Company Overview

Tiziana Life Sciences (NASDAQ: TLSA) is a dual-listed clinical stage company developing targeted therapeutics to transform treatment of liver diseases, inflammatory diseases, and cancer. Our clinical pipeline includes drug assets for Crohn's, and hepatocellular carcinoma. Tiziana’s two lead drug candidates, Foralumab and Milciclib, uniquely target the root cause of diseases with large unmet needs in multibillion-dollar markets. Tiziana is accelerating development of anti-IL6 receptor monoclonal antibody (mAb) for treatment of COVID-19 lung inflammation. Tiziana is a market leader in the invention of proprietary technology for oral, nasal and inhaled formulation to transform immunotherapies with Monoclonal Antibodies currently administered intravenously. Also, Tiziana has a robust and growing patent portfolio.

    development pipeline chart

  • Transformational platform technologies
    • Proprietary oral, nasal and inhaled formulation technologies to transform immunotherapies with Monoclonal Antibodies currently administered intravenously

  • Phase 2 oral immunotherapy study for Crohn’s Disease (CD)
    • Phase 2 clinical study with orally administered Foralumab, a fully human anti-CD3 mAb

  • Launching clinical study of COVID-19 monoclonal antibody
    • Innovative technology enables direct delivery of anti-IL6 receptor monoclonal antibodies into the lung using a handheld inhaler or nebuliser

  • Strong intellectual property protections
    • 174 foreign patents and 19 U.S. patents issued

  • Planned spinout of genomics-based personalized medicine businesses
    • StemPrintER is a superior breast cancer prognostic test versus Oncotype DX 40% more accurate in head-to-head study versus Oncotype DX Exact Sciences acquired Oncotype DX for $2.8 billion

  • Proven leadership team with ‘bench to market’ experience
    • Strong entrepreneurial success in biotech deals; CEO: co-founder Synergy Pharma; Executive Chairman founded and chaired two biotechs with $2B+ market caps Exemplary scientific advisory board with world renowned key opinion leaders